tbuckley/cabot-search huggingface dataset:
Adolescent Health—Not Just for Adolescent Specialists
Authors: Catherine D. Shubkin, Keith J. Loud
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
1122P Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases
Authors: C. Berking, D. Schadendorf, M. Weichenthal, T. Eigentler, P. Mohr, K. Schober, F. Kiecker, C. Loquai, D. Debus, R. Gutzmer, U. Leiter-Stöppke
Journal: Annals of Oncology (2020)
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
Authors: Jacopo Troisi, Antonio Raffone, Antonio Travaglino, Gaetano Belli, Carmen Belli, Santosh Anand, Luigi Giugliano, Pierpaolo Cavallo, Giovanni Scala, Steven Symes, Sean Richards, David Adair, Alessio Fasano, Vincenzo Bottigliero, Maurizio Guida
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic cancer. Its early detection is advisable because 20% of women have advanced disease at the time of diagnosis. <h3>Objective</h3> To clinically validate a metabolomics-based classification algorithm as a screening test for EC. <h3>Design, Setting, and Participants</h3> This diagnostic study enrolled 2 cohorts. A multicenter prospective cohort, with 50 cases (postmenopausal women with EC; International Federation of Gynecology and Obstetrics stage I-III and grade G1-G3) and 70 controls (no EC but matched on age, years from menopause, tobacco use, and comorbidities), was used to train multiple classification models. The accuracy of each trained model was then used as a statistical weight to produce an ensemble machine learning algorithm for testing, which was validated with a subsequent prospective cohort of 1430 postmenopausal women. The study was conducted at the San Giovanni di Dio e Ruggi d'Aragona University Hospital of Salerno (Italy) and Lega Italiana per la Lotta contro i Tumori clinic in Avellino (Italy). Data collection was conducted from January 2018 to February 2019, and analysis was conducted from January to March 2019. <h3>Main Outcomes and Measures</h3> The presence or absence of EC based on evaluation of the blood metabolome. Metabolites were extracted from dried blood samples from all participants and analyzed by gas chromatography–mass spectrometry. A confusion matrix was used to summarize test results. Performance indices included sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and accuracy. Confirmation or exclusion of EC in women with a positive test result was by means of hysteroscopy. Participants with negative results were followed up 1 year after enrollment to investigate the appearance of EC signs. <h3>Results</h3> The study population consisted of 1550 postmenopausal women. The mean (SD) age was 68.2 (11.7) years for participants with no EC in the training cohort, 69.4 (13.8) years for women with EC in the training cohort, and 59.7 (7.7) years for women in the validation cohort. Application of the ensemble machine learning to the validation cohort resulted in 16 true-positives, 2 false-positives, and 0 false-negatives, and it correctly classified more than 99% of samples. Disease prevalence was 1.12% (16 of 1430). <h3>Conclusions and Relevance</h3> In this study, dried blood metabolomic profile was used to assess the presence or absence of EC in postmenopausal women not receiving hormonal therapy with greater than 99% accuracy.
1249P PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark
Authors: D. Cronin-Fenton, T. Dalvi, N. Movva, L. Pedersen, H. Hansen, J. Fryzek, A. Mellemgaard, T. Rasmussen, A.B. Klein, S. Hamilton-Dutoit, M. Nørgaard
Journal: Annals of Oncology (2020)
1816MO ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey
Authors: T. Smit, A. Chan, M.R. Chasen, R. Bhargava, S. Bošnjak, A. Zilic, J.T. Chia, A.A. Jabbar, Z. Yaxiong, M. de Necker, T.V. Mhazo, L. Heyman, B.L. Rapoport
Journal: Annals of Oncology (2020)
Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer
Authors: Sheng Zhang, Cheng Kong, Yongzhi Yang, Sanjun Cai, Xinxiang Li, Guoxiang Cai, Yanlei Ma
Journal: Theranostics (2020)

Background: The oral microbiome may play an important role in colorectal carcinogenesis. However, few studies have investigated the association between oral microbiome and the development of colorectal cancer (CRC). We aimed to investigate whether oral health-colorectal tumor association has an underlying microbial basis, in the quest for novel non-invasive biomarkers for CRC. Methods: We collected oral swab samples from 161 patients with CRC, 34 patients with colorectal adenoma (CRA), and 58 healthy volunteers. The oral microbiota was assessed using 16S rRNA sequencing. We characterized oral microbiome, identified microbial markers, constructed and validated colorectal tumor (CRA and CRC) classifier. Results: Oral microbial composition and diversity were significantly different among the three groups, and the CRA group had the highest diversity. Analysis of the functional potential of oral microbiota demonstrated that the pathway involving cell motility was overrepresented in the CRA and CRC groups relative to that in the healthy controls. Moreover, a random forest model was constructed based on oral microbial markers, which could distinguish the colorectal tumor groups from the healthy controls and achieve a powerful classification potential in the discovery and validation cohorts. Conclusion: This study suggests a potential association between oral microbiome dysbiosis and colorectal cancer. Oral microbiota-based biomarkers may be helpful in predicting the risks for the development of CRA and CRC.
434P Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database
Authors: C.S. Karapetis, H. Liu, M. Sorich, J. Fiskum, A. Grothey, R.A. Adams, A. Venook, V. Heinemann, H.J. Lenz, T. Yoshino, J.R. Zalcberg, B. Chibaudel, M.E. Buyse, A. De Gramont, Q. Shi
Journal: Annals of Oncology (2020)
655P Prognostic significance of docetaxel (D) plus androgen-deprivation therapy (ADT) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) according to extent of disease: A study of real-world data
Authors: L. Notario, J.M. Piulats, N. Sala, U. Ferrándiz, A. González, O. Etxániz, S. Villà, O. Buisan, A. Boladeras, L. Heras, L. Del Carpio, A. Roselló, P. Barretina, C. Fina, J.C. Pardo, J.M. Suárez, J. Comet, X. Garcia del Muro, A. Esteve, A. Font
Journal: Annals of Oncology (2020)
1201P The role of a mini tumour mutational burden (TMB) score generated with a customized NGS panel to predict benefit from immunotherapy
Authors: P. Lombardi, V. Gambardella, N. Tarazona, J.A. Carbonell-Asins, J. Martín-Arana, P. Rentero-Garrido, J.V. Montón-Bueno, I. Gonzalez-Barrallo, G. Bruixola, J.M. Cejalvo, P. Martín-Martorell, R. Tébar-Martínez, S. Blesa, E. Seda, J.A. Pérez-Fidalgo, A. Insa Mollá, T. Fleitas, S. Zúñiga-Trejos, A. Cervantes, D. Roda
Journal: Annals of Oncology (2020)
621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
Authors: J.A. Arranz Arija, E.Y. Yu, J.M. Piulats, G. Gravis, B. Laguerre, S. Oudard, P.C. Fong, M.P. Kolinsky, M. Augustin, T. Todenhöfer, A.E. Kam, H. Gurney, A. Tafreshi, M. Retz, W.R. Berry, N. Mar, H. Wu, P. Qiu, C. Schloss, J.S. de Bono
Journal: Annals of Oncology (2020)
Epigenetic Age Acceleration and Chronic Health Conditions Among Adult Survivors of Childhood Cancer
Authors: Na Qin, Zhenghong Li, Nan Song, Carmen L Wilson, John Easton, Heather Mulder, Emily Plyler, Geoffrey Neale, Emily Walker, Xin Zhou, Haitao Pan, Melissa M Hudson, Yutaka Yasui, Leslie L Robison, Jinghui Zhang, Kirsten K Ness, Zhaoming Wang
Journal: JNCI Journal of the National Cancer Institute (2020)

Mounting evidence supports the occurrence of accelerating aging among long-term survivors of childhood cancer. We aimed to investigate epigenetic age acceleration (EAA) in survivors and evaluate associations between EAA, treatment exposures, health behaviors, and chronic health conditions (CHCs).Genome-wide methylation data were generated with Infinium EPIC BeadChip on blood-derived DNA from 2139 survivors and 282 frequency matched controls from the St Jude Lifetime Cohort Study. EAAs were estimated as residuals from a linear regression of epigenetic age (Levine's clock) against chronological age. Adjusted least square mean (ALSM) of EAA was calculated and compared between survivors and controls, across treatment exposures and health behaviors. Associations of EAA with 20 clinically assessed CHCs were evaluated with multivariable piecewise-exponential models. All statistical tests for P values below were 2-sided.EAA was statistically significantly higher in survivors than controls (ALSM = 0.63, 95% confidence interval [CI] = 0.26 to 1.01 vs -3.61, 95% CI = -4.43 to 2.80). In a multivariable model among survivors, statistically significantly higher EAA (P < .05) was observed in those exposed to chest radiotherapy, abdomen or pelvic radiotherapy, alkylating agents, glucocorticoids, or epipodophyllotoxins. Compared with survivors with favorable health behaviors (ALSM = 0.26, 95% CI=-0.36 to 0.87), EAA was statistically significantly higher among survivors with intermediate (ALSM = 1.07, 95% CI = 0.59 to 1.54) or unfavorable health behaviors (ALSM = 1.45, 95% CI = 0.60 to 2.30). In time-to-event analyses, statistically significant associations were identified between EAA tertiles and incidence of 7 CHCs: hypertension (3rd vs 1st tertile, relative rate [RR] = 1.83, 95% CI = 1.17 to 2.83), myocardial infarction (RR = 2.91, 95% CI = 1.27 to 7.21), obesity (RR = 1.39, 95% CI = 1.17 to 1.66), obstructive pulmonary deficit (RR = 1.86, 95% CI = 0.95 to 3.77), peripheral motor neuropathy (RR = 2.89, 95% CI = 1.24 to 6.97), peripheral sensory neuropathy (RR = 2.04, 95% CI = 0.99 to 4.26), and pulmonary diffusion deficits (RR = 2.75, 95% CI = 0.95 to 7.63).EAA is statistically significantly higher in survivors of childhood cancer than in noncancer controls and is associated with specific treatment exposures, unfavorable health behaviors, and presence of specific CHCs.
Liver X receptor β is required for the survival of single-positive thymocytes by regulating IL-7Rα expression
Authors: Huang Huang, Xiaoping Wu, Dongwei Meng, Yizhou Feng, Lan Zhou, Zhenyu Liu, Shupei Tang, Xueqin Li, Yi Cao, Haiyang He, Zhunyi Xie, Jingbo Zhang, Yongwen Chen, Tingting Zhao, Yuzhang Wu, Xinyuan Zhou
Journal: Cellular and Molecular Immunology (2020)
1119P Targeted treatment and immunotherapy in older patients with advanced melanoma: A single institution real-life experience
Authors: C. Pereira, D. Martins-Branco, C. Valente Bexiga, A.M. Monteiro, H. Nunes, A. Luís, E. Gouveia, A. Moreira, M.J. Passos
Journal: Annals of Oncology (2020)
1078MO MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma patients
Authors: K. Bol, M. Bloemendal, W. van Willigen, G. Schreibelt, S. Hins-de Bree, A. de Goede, A.A.M. Van der Veldt, C. Figdor, J.W.B. de Groot, J. de Wilt, J. Textor, W.R. Gerritsen, J. De Vries
Journal: Annals of Oncology (2020)
594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients
Authors: L.R. Hoes, H. van der Wijngaart, J.M. van Berge Henegouwen, L.J. Zeverijn, D.L. van der Velden, P. Roepman, W. de Leng, A.M.L. Jansen, E. van Werkhoven, A. Huitema, E.F. Smit, C. Van Herpen, M. Labots, A. Hoeben, H. Morreau, M.P. Lolkema, E. Cuppen, H. Gelderblom, H.M.W. Verheul, E.E. Voest
Journal: Annals of Oncology (2020)
312P Real-world (RW) multi-country study of BRCA1/2 mutation (BRCA1/2mut) testing trends among adult patients (pts) with HER2− advanced breast cancer (ABC)
Authors: R. Mahtani, A. Niyazov, K. Lewis, L. Massey, A. Rider, B. Arondekar, M.P. Lux
Journal: Annals of Oncology (2020)
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group
Authors: Sabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, Danielle A van der Windt, Maarten de Wit, Thasia G Woodworth, Caroline A Flurey, Dorcas Beaton, Beverley Shea, Reuben Escorpizo, Daniel E Furst, Josef S Smolen, Karine Toupin-April, Annelies Boonen, Marieke Voshaar, Torkell Ellingsen, George A Wells, Barnaby C Reeves, Lyn March, Peter Tugwell, Robin Christensen
Journal: Annals of the Rheumatic Diseases (2020)

The Outcome Measures in Rheumatology Initiative established the Contextual Factors Working Group to guide the understanding, identification and handling of contextual factors for clinical trials. In clinical research, different uses of the term 'contextual factors' exist. This study explores the perspectives of researchers (including clinicians) and patients in defining 'contextual factor' and its related terminology, identifying such factors and accounting for them in trials across rheumatology.We conducted individual semistructured interviews with researchers (including clinicians) who have experience within the field of contextual factors in clinical trials or other potentially relevant areas, and small focus group interviews with patients with rheumatic conditions. We transcribed the interviews and applied qualitative content analysis.We interviewed 12 researchers and 7 patients. Researcher's and patient's descriptions of contextual factors were categorised into two broad themes, each comprising two contextual factors types. The 'treatment effect' theme focused on factors explaining variations in treatment effects (A) among patients and (B) among studies. The 'outcome measurement' theme focused on factors that explain (C) variations in the measurement result itself (apart from actual changes/differences in the outcome) and (D) variations in the outcome itself (beside treatment of interest). Methods for identifying and handling contextual factors differed among these themes and types.Two main themes for contextual factors with four types of contextual factors were identified based on input from researchers and patients. This will guide operationalisation of contextual factors. Further research should refine our findings and establish consensus among relevant stakeholders.
Construction of Enzyme Nanoreactors to Enable Tumor Microenvironment Modulation and Enhanced Cancer Treatment
Authors: Xiaowen Liu, Yu Hao, Rachela Popovtzer, Liangzhu Feng, Zhuang Liu
Journal: Advanced Healthcare Materials (2020)

Enzymes play pivotal roles in regulating and maintaining the normal functions of all living systems, and some of them are extensively employed for diagnosis and treatment of diverse diseases. More recently, several kinds of enzymes with unique catalytic activities have been found to be promising options to directly suppress tumor growth and/or augment the therapeutic efficacy of other treatments by modulating the hostile tumor microenvironment (TME), which is reported to negatively impair the therapeutic efficacy of different cancer treatments. In this review, first a summary is presented on the chemical approaches utilized for the construction of distinct enzyme nanoreactors with well-retained catalytic performance and reduced immunogenicity. Then, the utilization of such enzyme nanoreactors in attenuating tumor hypoxia, modulating extracellular matrix, and amplifying tumor oxidative stress is discussed in depth. Afterward, some perspectives are presented on the future development of such enzyme nanoreactors in TME modulation and enhanced cancer treatment.
138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin
Authors: N. Mehra, K. Fizazi, A.D. Laird, P. Barthélémy, R. Delva, T. Dorff, M. Maruzzo, A. Stirling, J-P. Machiels, H. Dumez, V. Renard, L.A. Albacker, J. Hopkins, H-C. Chen, M. Mata, N. Di Santo, C.G. Healy, I.M. van Oort, C. Buttigliero, J.S. de Bono
Journal: Annals of Oncology (2020)
1117P Immunotherapy in octogenarian and nonagenarian metastatic melanoma patients
Authors: B. Cybulska-Stopa, M. Ziętek, A.M.M. Czarnecka, K. Piejko, L. Galus, B.E. Ziolkowska, S. Kieszko, N. Kempa-Kamińska, J. Calik, T. Zemelka, J. Rolski, P. Rogala, T. Kubiatowski, R. Suwinski, J. Mackiewicz, P. Rutkowski
Journal: Annals of Oncology (2020)
22P Salicylidene Acylhydrazides attenuate SH-SY5Y neuroblastoma cell survival through mitotic regulator Speedy/RINGO and ERK/ MAPK - PI3K/ AKT pathways
Authors: O. Tanriverdi, S. Arziman, S. Kucukvardar, A. Yildiz
Journal: Annals of Oncology (2020)
1814MO Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: A randomized, open-label trial
Authors: A. Sharma, S. Bakhshi, A. Sharma, D. Pushpam, A. Tiwari, A. Garg, D. Dhawan, R. Bisht
Journal: Annals of Oncology (2020)
172P Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis
Authors: S. Bruzas, S. Kümmel, N. Harbeck, P. Schmid, J. Cortés, C. Seiberling, O. Chiari, H. Harrach, B. Ataseven, M. Dyson, E. Traut, I. Theuerkauf, D. Gebauer, O. Gluz, M. Reinisch
Journal: Annals of Oncology (2020)
49P Role of microRNAs in a panel of human cervical cancer cell lines
Authors: R.L. Causin, M.R. Nunes, L.S. da Silva, A.J.A. de Freitas, A.C. Carvalho, L.C. Sichero, L.L. Villa, V.A.O. Silva, R.M.V. Reis, M.M.C. Marques
Journal: Annals of Oncology (2020)
2001P Adenoid cystic carcinomas (ACC) of the trachea, salivary gland, breast: A comparative comprehensive genomic profiling (CGP) study
Authors: J. Elvin, N.A. Danziger, J. Corines, J-A. Vergilio, J.K. Killian, D.I. Lin, E. Williams, J. Tse, S. Ramkissoon, E. Severson, A. Hemmerich, C. Edgerly, D. Duncan, R. Huang, A.B. Schrock, B. Alexander, J. Venstrom, P. Reddy, K. McGregor, J.S. Ross
Journal: Annals of Oncology (2020)
1742P Outcomes of the reorganisation of a medical oncology department during the COVID-19 pandemic: Real-word experience
Authors: S.A. Duarte, P. Liu, J. Liz Pimenta, K. Ladeira, I. Grilo, E. Ferreira, P.M. Araujo, M. Rocha, P. Gago, D. Azevedo, M.C. Branco, R. Gomes, A. Teira, T. Sarmento, M. Sousa
Journal: Annals of Oncology (2020)
1371P Randomized phase II trial of pemetrexed with or without bevacizumab maintenance after cisplatin, pemetrexed and bevacizumab in advanced non-squamous, non-small cell lung cancer (TORG1321)
Authors: T. Kondo, T. Kasai, K. Mori, H. Saito, K. Nishikawa, S. Otsu, N. Seki, Y. Ichikawa, A. Bessho, H. Tanaka, H. Yamaguchi, T. Kaburagi, K. Kanazawa, Y. Komase, K. Minato, Y. Misumi, R. Morinaga, K. Mori, J. Ohtake, H. Okamoto
Journal: Annals of Oncology (2020)
1709P Cancer patients' perspectives on the real-world impact of COVID-19 pandemic: A multidisciplinary survey
Authors: K.K.H. Bao, K.M. Cheung, J.C.-H. Chow, C.W.L. Leung, W. Tsui, A. Lau, T. Tse, S. Wan, M. Kwok, K.H. Wong
Journal: Annals of Oncology (2020)
Abstract IA26: Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums
Authors: Brian I. Rini
Journal: Clinical Cancer Research (2020)

SARS-CoV-2 and the resulting disease, COVID-19, has led to a global pandemic with broad impact on the delivery of medical care. Cancer patients may be especially vulnerable to both infection and adverse outcomes from COVID due to a number of factors including advanced age, immunosuppression from disease and/or anticancer therapy, and heightened interaction with the medical system. Several cohort studies have been launched to more fully understand risk factors for death and other adverse outcomes in patients with active or remote cancer. CCC-19 is a cohort study involving more than 100 institutions that enter data into a REDCaP database regarding patient demographics, cancer type and treatment details, and outcome of COVID infection. All patients have documented SARS-CoV-2 PCR positive and/or clinical symptoms consistent with COVID, in addition to an ongoing or past history of invasive malignancy. The initial analysis of this cohort study (n=928; Kuderer et al., Lancet 2020) demonstrated a 13% mortality rate and revealed several factors associated with an increased mortality including advanced age, male gender, greater number of comorbidities, worse ECOG performance status, and progressive cancer. Recent cancer surgery and receipt of cytotoxic or other systemic anticancer therapy was not associated with worse outcome, although small patient numbers in some subsets precluded definitive conclusions. At present, there are approximately 3,000 patients entered into this database and updated analyses will be presented. In addition to this effort, a number of other societies have created similar databases including ASH, ASCO, and ESMO. These complementary efforts will allow a global assessment of the impact of COVID on cancer patients including mortality and adverse outcomes in addition to cancer-specific outcomes. Last, the NCI COVID-19 in Cancer Patients Study (NCCAPS) is a prospective study in patients with active cancer and recent SARS-CoV-2 infection. This 2,000-patient study is open to accrual and will prospectively define both the impact of COVID on cancer and also cancer status and treatment on COVID outcome. In addition, biospecimen collection in this study will examine genetic predisposition, cytokine and coagulopathic parameters, and serologic outcomes. Collectively, these retrospective and prospective efforts will enable a more granular understanding of COVID in cancer patients to enable both appropriate cancer care delivery and improvement in outcomes in cancer patients with COVID infection.Citation Format: Brian I. Rini, (on behalf of the CCC-19 Consortium). Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr IA26.
556P Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116)
Authors: E.P. Hamilton, M.R. Patel, C.C. Gunderson, K. Wride, D. Lepley, R. Dusek, M. Liao, T. Cameron
Journal: Annals of Oncology (2020)